ATTY DOCKET NO. APPLICATION 9439-016 10/765,792	
Y EISTOF REFERENCES CITED BY REQUESTOR	•
PEISTOF REFERENCES CITED BY REQUESTOR APPLICANT Michael A. Zeligs FILING DATE: GROUP	
U.S. PATENT DOCUMENTS	
*EXAMINER INITIAL DOCUMENT NUMBER DATE NAME CLASS SUBCLASS	FILING DATE IF APPROPRIAT
N 6 A01 6,613,792 09/02/2003 Ellenberger et al.	
A02 6,399,645 07/04/2002 Bell et al.	
A03 6,086,915 07/11/2000 Zeligs	
A04 5,948,808 09/07/1999 Safe	
N° 6 A05 5,830,887 11/03/1998 Kelly	
FOREIGN PATENT DOCUMENTS	
DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS	TRANSLATIO
	YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
J € C01	Arbeit, JM et al., "Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice", 1996 Apr., Proc Natl Acad Sci, USA 93:2930-2935.				
C02	Baugh SM et al., "Treatment of cervical dysplasia with indole-3-carbinol" in The Ray A. Barlow Scientific Symposium, 1998 Jan 23, Shreveport: The Center for Excellence in Cancer Research, Treatment and Education, Louisians State University Medical Center, Shreveport (LA), pg. 3.				
C03	Bell, MC et al., "Placebo-controlled Trial of Indole-3-Carbinol in the Treatment of Cervical Dysplasia", 1999 March, Gynecol. Oncol. 72:446				
C04	Bell, MC et al., "Placebo-Controlled Trial of Indole-3-Carbinol in the Treatment of CIN", 2000, Gynecologic Oncology, 78:123-129.				
C05	BioResponse-DIM Indolplex Product Information Brochure, 1998 Dec 15.				
C06	Bradfield et al., "High-performance liquid chromatographic analysis of anticarcinogenic indoles in Brassica oleracea" 1987, J Agric Food Chem 35:46-49				
C07	Bradlow et al., "2-hydroxyestrone: the 'good' estrogen", 1996, J Endocrin 150:S259-S265				
C08	Cancer Medicine 3rd edition, 1993, JF Holland ed., Lea & Febiger, Malvern, PA p. 1633.				
C09	Chen et al., "Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindoylmethane", 1998, Carcinogenesis 19:1631-1639				
C10	December 1998 Bioresponse Letter, 1998 Dec 29.				
CII	Greenblatt et al., "Clinical studies with an anti-gonadotropin -danazol", 1971, Fertil Steril 22:102.				
C12	Ho et al., "Urinary 2/16alpha-hydroestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk", 1998, Ann Acad Med Singapore 27:294-9				
C13	Jin et al., "Indole-3-carbinol prevents cervical cancer in human papillomavirus type 16 (HPV16) transgenic mice", 1999, Cancer Res 59"3991-7				
1.6 C14	Komura et al., "Catecholestrogen as a natural antioxidant", 1996, Ann NY Acad Sci 786:419-29				

CIS	Michnovicz et al., "Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans", 1997, J Natl Cancer Inst 89:718-23	
C16	Molecular Biology of the Cell 2 nd ed., 1989, Alberts, B et al., Garland Publishing, Inc., New York, pp. 1193-1194, 1204-1206.	
C17	Ponten J and Guo Z, "Precancer of the Human Cervix", 1998, Cancer Surveys 32:201-229.	
C18	Rosen et al., "Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis", 1998, Otolaryngol Head Neck Surg 118:810-5	
C19	Schneider et al., "Abnormal oxidative metabolism of estradiol in women with breast cancer", 1982, Proc Natl Acad Sci USA 79:3047-52	
C20	of endometriosis", 1987, Gynecol Endocrinol 1:51	
C21	Thomas et al., "Impact of gestrinone on the course of asymptomatic endometriosis", 1987, Br Med J 294:272.	
C22	Tzingounis et al., "Modern approach to endometriosis", 1997, Annals New York Acad Sci 816:320-330.	
C23	Yuan F et al., "Prevention of Papillomavirus initiated cancer by the phytochemical Indole-3-Carbinol", Proceedings of the 17th International Papillomavirus Conference, 1999 Jan 9-15, pg. 73.	
C24	Zeligs MA, "Diet and Estrogen Status: The Cruciferous Connection", 1998, J Med Food, 1:67-82.	
	C16 C17 C18 C19 C20 C21 C22 C23	

		· ·	
EXAMINER	DATE CONSIDERED		4/18/07
•	L		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.